EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacokinetics, safety, and efficacy of high-concentration intratympanic dexamethasone for sudden sensorineural hearing loss: An integrated non-human primate and clinical study

Shuyue Zhang, Fei Wang, Shujing Jin, Mingjian Zhang, Jigang Zhang, Wenyuan Xue, Yixin Zha, Guang Jin, Ximei Wang, Pin Dong, Yuying Liu, Xueying Ding

European Journal of Pharmaceutical Sciences · 2026-12 · 227 · 107657

DOI: 10.1016/j.ejps.2026.107657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2026-12. Verfasst von Shuyue Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Dexamethasone, Hearing Loss, Sensorineural, Hearing Loss, Sudden, Glucocorticoids. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intratympanic (IT) corticosteroid therapy is a well-established intervention for sudden sensorineural hearing loss (SSNHL), yet its optimal dosing remains undefined. This study aimed to conduct an integrated preclinical and clinical evaluation of high-concentration IT dexamethasone phosphate (Dex-P), focusing on pharmacokinetics (PK), safety, and preliminary efficacy. The study comprised three parts. Part A and Part B evaluated the perilymph and plasma PK of cynomolgus monkeys. Part C assessed the plasma PK, safety, and hearing recovery of standard treatment-failure SSNHL patients following three IT injections of Dex-P (20 or 40 mg/mL, q3d). Preclinical PK data demonstrated the superiority of IT treatment, achieving high and sustained drug levels in the perilymph that were not detected via systemic administration. High-concentration IT injection led to disproportionate increase in perilymph exposure relative to the dose increment, while the corresponding plasma exposure was approximately following the dose proportionality. In SSNHL patients, high-concentration IT administration was well-tolerated with no dose-limiting toxicity. Systemic exposure increased approximately in proportion to the dose increment, and no significant accumulation was observed. Hearing improvement was modest. Although not statistically significant, a greater pure-tone average improvement was observed in the 40 mg/mL group (5.69 dB) compared to the 20 mg/mL group (3.06 dB). High-concentration IT Dex-P (up to 40 mg/mL) is a feasible and safe option for the salvage treatment of SSNHL. The trend toward better hearing outcomes, combined with its enhanced local target-site exposure and favourable safety profile, provides a rationale for further investigation in larger, controlled clinical trials to optimize therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneHearing Loss, SensorineuralHearing Loss, SuddenGlucocorticoidsAnimalsInjection, IntratympanicMaleFemalePerilymphMacaca fascicularisHumansTreatment Outcome

Stichwörter der Autor:innen

DexamethasoneInner earIntratympanic injectionPerilymphSudden sensorineural hearing loss

Substanzen

Dexamethasonedexamethasone 21-phosphateGlucocorticoids

Autor:innen und Institutionen

  • Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Otolaryngology, Head and Neck Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Beijing Heyu Pharmaceutical Technology Co., Ltd, Beijing, China.
  • Department of Otolaryngology, Head and Neck Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: dongpin64@aliyun.com.
  • Department of Otolaryngology, Head and Neck Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: lyyiuuing@163.com.
  • Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: dingxueying@126.com.

Zitieren

APA

Zhang, S., Wang, F., Jin, S., Zhang, M., Zhang, J., Xue, W., Zha, Y., Jin, G., Wang, X., Dong, P., Liu, Y., & Ding, X. (2026). Pharmacokinetics, safety, and efficacy of high-concentration intratympanic dexamethasone for sudden sensorineural hearing loss: An integrated non-human primate and clinical study. European Journal of Pharmaceutical Sciences, 227, 107657. https://doi.org/10.1016/j.ejps.2026.107657

Vancouver

Zhang S, Wang F, Jin S, Zhang M, Zhang J, Xue W, et al. Pharmacokinetics, safety, and efficacy of high-concentration intratympanic dexamethasone for sudden sensorineural hearing loss: An integrated non-human primate and clinical study. European Journal of Pharmaceutical Sciences. 2026;227:107657. doi:10.1016/j.ejps.2026.107657

BibTeX
@article{Zhang2026,
  author = {Zhang, Shuyue and Wang, Fei and Jin, Shujing and Zhang, Mingjian and Zhang, Jigang and Xue, Wenyuan and Zha, Yixin and Jin, Guang and Wang, Ximei and Dong, Pin and Liu, Yuying and Ding, Xueying},
  title = {Pharmacokinetics, safety, and efficacy of high-concentration intratympanic dexamethasone for sudden sensorineural hearing loss: An integrated non-human primate and clinical study},
  journal = {European Journal of Pharmaceutical Sciences},
  year = {2026},
  volume = {227},
  pages = {107657},
  doi = {10.1016/j.ejps.2026.107657}
}
Kostenlos starten →